000			01736 a2200505 4500
005			20250517171446.0
264		0	_c20180418
008			201804s 0 0 eng d
022			_a1873-2623
024	7		_a10.1016/j.transproceed.2017.06.007 _2doi
040			_aNLM _beng _cNLM
100	1		_aBoyle, S M
245	0	0	_aDonor-Derived Metastatic Melanoma and Checkpoint Inhibition. _h[electronic resource]
260			_bTransplantation proceedings _cSep 2017
300			_a1551-1554 p. _bdigital
500			_aPublication Type: Case Reports; Journal Article
650	0	4	_aAllografts _xpathology
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCheckpoint Kinase 1 _xantagonists & inhibitors
650	0	4	_aCheckpoint Kinase 2 _xantagonists & inhibitors
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aKidney _xpathology
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aKidney Transplantation _xadverse effects
650	0	4	_aLiver Neoplasms _xdrug therapy
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aNivolumab
650	0	4	_aOximes _xtherapeutic use
650	0	4	_aPyridones _xtherapeutic use
650	0	4	_aPyrimidinones _xtherapeutic use
650	0	4	_aTissue Donors
700	1		_aAli, N
700	1		_aOlszanski, A J
700	1		_aPark, D J
700	1		_aXiao, G
700	1		_aGuy, S
700	1		_aDoyle, A M
773	0		_tTransplantation proceedings _gvol. 49 _gno. 7 _gp. 1551-1554
856	4	0	_uhttps://doi.org/10.1016/j.transproceed.2017.06.007 _zAvailable from publisher's website
999			_c27495324 _d27495324